InvestorsHub Logo
Followers 172
Posts 17650
Boards Moderated 0
Alias Born 03/02/2012

Re: HighPeaks post# 1818835

Sunday, 10/22/2017 11:21:27 AM

Sunday, October 22, 2017 11:21:27 AM

Post# of 2337536
GOVX pharma .042, real co., run began Friday!!
http://stockcharts.com/h-sc/ui?s=govx

Real BOD!
https://www.geovax.com/corporate-governance/board-of-directors-corporate-governance.html

S-1 form in September was going to dump 166M shares into market. It's been canceled! Good news coming, imho!
https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12269293

About GeoVax
GeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its MVA-VLP vaccine platforms. The Company's HIV vaccine for the clade B epidemic in the Americas and Europe is advancing in human trials conducted by the HIV Vaccine Trials Network. Preclinical programs are focused on preventive vaccines for Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections and cancers. GeoVax's vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine, mimicking a natural infection and stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. For more information, visit https://www.geovax.com/.



Zacks says, .25 valuation!
https://www.geovax.com/images/GOVX_SCIR-2017-08-22.PDF

Too much good news coming out for GOVX to go unnoticed, imho!

https://finance.yahoo.com/news/geovax-reports-significant-advance-hiv-180000573.html

https://www.geovax.com/clinical-pipeline.html

Significant advances from Duke Medical, Unv. Penn, Alamos! This is HUGE!!!

"This as an important advance in the development of a vaccine with the potential to elicit broadly neutralizing antibody to the CD4 binding site," Dr. Robinson continued. "We intend to push this technology forward for the development of a vaccine for the clade C subtype of HIV that is devastating populations in Africa."



A/S 600M, Float, 65M

http://www.otcmarkets.com/stock/GOVX/profile

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.